Tag: Daxor

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting

Coronary/Structural Heart by 0 comments

Two New Studies Presented at the American Heart Association Scientific Sessions 2021, Adoption of Technology Reported as “Excellent” and “Valuable” by Lead Authors Oak Ridge, TN, Nov. 16, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement […]

Continue Reading →

Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100® (Blood Volume Analyzer) with the United States Department of Veterans Affairs

Coronary/Structural Heart by 0 comments

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a multi-center clinical trial with two Veterans Affairs Medical Centers to evaluate Blood Volume […]

Continue Reading →

DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

Coronary/Structural Heart by 0 comments

NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), […]

Continue Reading →

Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

Coronary/Structural Heart by 0 comments

NEW YORK, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major […]

Continue Reading →

New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020

Coronary/Structural Heart by 0 comments

NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s […]

Continue Reading →

DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS

Coronary/Structural Heart by 0 comments

Enrollment Commences Using the BVA-100® Diagnostic Blood Test NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of […]

Continue Reading →
1 2 3